

NEWPORT PHASE III DRUGS MODULE

INTELLIGENCE ON PRODUCTS STILL IN PHASE III CLINICAL TRIALS



WHAT PHASE III DRUGS CAN HELP YOU DO

- Conduct better, earlier product targeting
- Monitor the competition
- Seek out partners earlier
- Anticipate line extensions for launched products
- Predict the strategies innovators will use to protect their franchise

HOW YOU BENEFIT

- Monthly intelligence updates
- Simple web-based interface
- Comprehensive training and technical support
- Integrated on-line help
- Zero cost deployment
- Secure, confidential hosted access

HOW TO SUBSCRIBE

The *Newport Phase III Drugs Module* is an optional subscription module that may be added on a per-seat basis to *Newport Premium™* (for Generics) or *Newport Global™* (for Generics) product configurations for an additional annual charge. A subscription to a base system is required before purchasing this module. To get a quotation, contact your account manager or visit science.thomsonreuters.com/info/sales

In today's hyper-competitive pharmaceutical industry, generic companies and API manufacturers need every advantage they can get over their rivals.

GAIN A COMPETITIVE EDGE BY TARGETING PRODUCTS EARLIER

The *Newport Phase III Drugs Module* enables you to target new development opportunities as soon as possible.

Seamlessly integrated into *Newport Global™* and *Newport Premium™*, *Phase III Drugs* extends the base system's coverage of APIs to include more than 400 compounds in late-stage development (Phase III clinical, registration or under review).

It includes patent, synthesis, and clinical development details for these late-stage compounds, equipping you to begin your targeting and competitive tracking processes earlier than ever before.

For pharmaceutical products that are already in the market, *Phase III Drugs* adds information about further clinical trials taking place, giving you insights into the possible line extensions or additional indications that are being pursued in different markets.

Two dedicated searches enable you to identify development-stage products by exacting criteria. You can review a launched drug's complete development history and receive email alerts as new drugs progress through the development pipeline.

PHASE III DRUGS HELPS YOUR STRATEGIC PLANNING TEAM TO:

- Identify opportunities that match your strategic needs and strengths years before launch
- Adjust your research timing, priorities, and resources based on competitive intelligence for products from Phase III through pre-launch
- Anticipate line-extensions for products in the market and strategies for protecting franchises

PHASE III DRUGS HELPS YOUR BUSINESS DEVELOPMENT TEAM TO:

- Profile candidate products for acquisition, alliances, licensing, or supply and manufacturing
- Track and monitor patenting and clinical trial activities for products of interest
- Evaluate candidate products against the earliest competitive intelligence

PHASE III DRUGS HELPS YOUR PRODUCT INTELLIGENCE TEAM TO:

- View regulatory filings, such as U.S. DMFs, for products still in Phase III clinical trials
- Explore chemical structure diagrams and routes of synthesis with patent and literature references
- Uncover additional indications being pursued for drugs in the marketplace

PHASE III DRUGS ALSO AIDS COMPANY AND PATENT INTELLIGENCE

The *Newport Phase III Drugs Module* can help your company intelligence team to monitor development portfolios of hundreds of companies, including for line extensions for launched products. It can also help your patent intelligence team to explore worldwide patent families and individual patents for products in Phase III clinical trials, pre-registration, registration, and pre-launch phases.


Development Programs		
▲ Development Program Name	Highest Development Program Status	Development Therapy At
APA-01 + atorvastatin (atherosclerosis), Phosphagenics	Discovery	Atherosclerosis
atorvastatin	Launched	Alzheimers disease; At Hyperlipidemia
atorvastatin + amlodipine	Launched	Angina; Atherosclerosis Hyperlipidemia; Hypert
atorvastatin + losartan (time-delayed, hypertension/ hyperlipidemia), Hanall/ Yuhon	Discovery	Hyperlipidemia; Hypert
ezetimibe + atorvastatin, Schering-Plough/Merck & Co	Phase 3 Clinical	Hypercholesterolemia
fenofibrate + atorvastatin (oral, MeltDose, hypercholesterolemia), LifeCycle	Phase 2 Clinical	Hypercholesterolemia; I
laropiprant + extended-release nicotinic acid + atorvastatin (lipid metabolism disorder), Merck & Co	Discovery	Lipid metabolism disord
torcetrapib + atorvastatin	Discontinued	Atherosclerosis, Hyper

© 2003 - 2009 THOMSON REUTERS

For both launched and Phase III drugs, get a snapshot of which additional development programs are being pursued and what status has been reached.



THOMSON REUTERS™



NEWPORT GENERIC DEALS MODULE

INTELLIGENCE AT YOUR FINGERTIP FOR YOUR NEXT DEAL

HOW TO SUBSCRIBE

The *Newport Generic Deals Module* is an optional subscription module that may be added on a per-seat basis to *Newport Premium™*, *Newport Global™*, and *Newport Sourcing™* product configurations for an additional annual charge. A subscription to a base system is required before purchasing this module. To get a quotation, contact your account manager or visit science.thomsonreuters.com/info/sales

WHAT GENERIC DEALS CAN HELP YOU DO

- Seek out partners and acquisition targets
- Anticipate moves by your competitors
- Improve and streamline your partner selection process and sourcing decisions
- Analyze deal making trends over the past 10 years and company growth strategies
- Evaluate potential acquisition targets

HOW YOU BENEFIT

- Monthly intelligence updates
- Simple web-based interface
- Comprehensive training and technical support
- Integrated on-line help
- Zero cost deployment
- Secure, confidential hosted access

GAIN A COMPETITIVE EDGE BY HAVING ALL THE FACTS AT HAND

The *Newport Generic Deals Module* provides you with all the facts you need to make a deal, choose a partner, scout the competition, or look for your next acquisition.

Seamlessly integrated into *Newport Sourcing™*, *Newport Global™* and *Newport Premium™*, *Generic Deals* contains detailed intelligence from Thomson Reuters on thousands of merger and acquisition, development, supply, manufacturing, joint venture, patent settlement, and authorized generic deals involving generic companies worldwide since 1999.

For each deal, and where applicable, you can explore the parties involved, their geographic location, announcement and transaction dates, source attribution, dollar value and percentage stake, the deal type and status, and a summary description.

A new focused search enables you to conduct comprehensive analysis of global generic deal-making activity. Email alerts advise you of the latest changes to deals being pursued and closed by the generic

industry worldwide.

GENERIC DEALS HELPS YOUR STRATEGIC PLANNING TEAM TO:

- Improve, inform and streamline your partner selection process
- Analyze deal making trends over the past 10 years and company growth strategies
- Evaluate potential acquisition targets
- Anticipate moves by your competitors

GENERIC DEALS HELPS YOUR BUSINESS DEVELOPMENT TEAM TO:

- Profile partners for acquisition, alliances, licensing, or supply and manufacturing deals
- Improve your product selection process and sourcing decisions

GENERIC DEALS ALSO AIDS COMPANY AND PATENT INTELLIGENCE

Generic Deals can help your company intelligence team to monitor deal-making activity by hundreds of companies. It can also help your product intelligence team to track and monitor deal-making around products of interest.

Scientific Head Offices

Americas

Philadelphia
+1 800 336 4474
+1 215 386 0100

Europe, Middle East and Africa

London +44 20 7433 4000

Asia Pacific

Singapore +65 6411 6888
Tokyo +81 3 5218 6500

For a complete office list visit:
scientific.thomsonreuters.com/contact

PH0906130e

Copyright © 2009 Thomson Reuters

Acquirer/Principal Company	Country	Target/Partner Company	Country	Deal Type	Status
Novartis AG	Switzerland	Hexal AG	Germany	MA	Completed
Novartis AG	Switzerland	Eon Labs Inc	US	MA	Completed
Novartis AG	Switzerland	Eon Labs Inc	US	MA	Completed
Novartis AG	Switzerland	Bristol-Myers Squibb Co-US Consumer Medicines Business	US	MA	Completed
Novartis Animal Health US Inc	US	Boehringer Ingelheim Vetmedica-Denagard Product Line	US	MA	Completed
Sandoz Farmaceutica Lda	Portugal	Bexal-Produtos Farmaceuticos SA	Portugal	MA	Completed
Novartis AG	Switzerland	Chiron Corp	US	MA	Completed
Novartis Pharma AG	Switzerland	NovTec Pharma Plc	UK	MA	Unconditional
Novartis Animal Health KK	Japan	LINECH Animal Health Co Ltd	Japan	MA	Completed
Novartis AG	Switzerland	Thommen Medical AG	Switzerland	MA	Completed
Novartis AG	Switzerland	Intercell AG	Austria	MA	Completed
Novartis AG	Switzerland	Akzon Inc	US	MA	Completed

New Deals pages for corporate groups display mergers and acquisitions, manufacturing and marketing alliances, litigation settlements, and other deals from the past 10 years.

Acquirer/Principal Company Name	Actavis Group HF
Acquirer/Principal Company Country	Iceland
Target/Partner Company Name	Endo Pharmaceuticals Holdings Inc
Target/Partner Company Country	Iceland
Date Announced	29 Feb 2009
Date Effective	
Date Terminated	
Value (\$M)	
Type	Patent Litigation Settlement
Products	oxymorphone hydrochloride

Summary
In February 2009, Actavis entered into a litigation settlement agreement with Endo Pharmaceuticals and Penwest Pharmaceutical regarding the product (oxymorphone hydrochloride) Extended Release Tablets CII.

Deal detail pages highlight the involved parties, dates, and values, and provide a short synopsis of the deal.



THOMSON REUTERS™